Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

413
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
413
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

435
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
435

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synergistic effects of partial enteral nutrition combined with Ustekinumab in induction and maintenance therapy for Crohn's disease: Real-world experience from a multicentre cohort.

Clinical nutrition (Edinburgh, Scotland)·2026
Same author

Nonlinear association between the triglyceride-cholesterol-body weight index and GLIM-defined hospital-acquired malnutrition among Chinese hospitalized adults: a multicenter prospective cohort study.

Journal of health, population, and nutrition·2026
Same author

Macrophage-Induced Senescent Cancer-Associated Fibroblasts Promote SASP-Mediated Chemoresistance in Colorectal Cancer.

Cancer research·2026
Same author

SMOC2 mediates GLI1+ mesenchymal cell-driven fibrostenosis and predicts postoperative recurrence in Crohn's disease.

Gut·2026
Same author

Long-term clinical and endoscopic efficacy of vedolizumab and therapeutic persistence in patients with ulcerative colitis in China: a multicenter observational study.

Intestinal research·2026
Same author

ZACP: enhancing skin lesion classification ability using zero attention and complete perception.

Visual computing for industry, biomedicine, and art·2026

Related Experiment Video

Updated: Jan 7, 2026

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

468

Risk-Stratified Biologic Efficacy in Ulcerative Colitis: A Multicenter Machine Learning Study.

Pingxin Zhang1,2, Chuhan Zhang1, Zishan Liu1

  • 1Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.

Inflammatory Bowel Diseases
|December 22, 2025
PubMed
Summary

A new random forest model accurately predicts ulcerative colitis (UC) progression, identifying patients who benefit most from biologic therapies. This tool aids in personalized UC management by stratifying risk for better treatment outcomes.

Keywords:
biologics efficacydisease progressionrisk stratificationulcerative colitis

More Related Videos

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.6K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

616

Related Experiment Videos

Last Updated: Jan 7, 2026

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

468
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.6K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

616

Area of Science:

  • Machine learning applications in gastroenterology
  • Predictive modeling for chronic disease management
  • Personalized medicine in inflammatory bowel disease

Background:

  • Ulcerative colitis (UC) presents a variable clinical course, making prognostication and treatment decisions challenging.
  • Existing methods for predicting UC progression and response to biologic therapies are insufficient.
  • There is a need for advanced tools to stratify UC patients for optimized therapeutic strategies.

Purpose of the Study:

  • To develop and validate a machine learning model for accurate risk stratification in ulcerative colitis (UC) patients.
  • To assess the model's utility in predicting disease progression and optimizing outcomes for patients receiving biologic therapies.

Main Methods:

  • A multicenter retrospective study involving 481 UC patients for training and 131 for external validation.
  • Development of four predictive models (Cox regression, logistic regression, random forest, XGBoost) for disease progression (treatment escalation, hospitalization, surgery).
  • Stratification of 235 biologic-treated UC patients into risk groups using the optimal model to evaluate outcomes like mucosal healing and relapse.

Main Results:

  • The random forest model showed superior predictive performance (AUC 0.959 training, 0.759 validation).
  • High-risk patients receiving biologics had significantly lower mucosal healing rates and higher risks of relapse, hospitalization, and acute severe UC compared to low-risk patients.
  • No significant differences were observed in serological remission, surgery rates, or the need for biologic switching between risk groups.

Conclusions:

  • The developed random forest model effectively stratifies UC patients, identifying distinct response patterns to biologic therapies.
  • The model differentiates patients who benefit from timely biologics versus those requiring intensified treatment strategies.
  • This predictive framework supports personalized UC management, emphasizing the need for prospective validation.